益生菌作为脏守护者:调节肠道微生物群以对抗糖尿病诱导的脏损伤
1Biology Department, Faculty of Science, Al-Baha University, Al-Baha 65779, Saudi Arabia.
Biology
|February 26, 2025
概括
在老鼠中,Lactobacillus acidophilus ATCC 4356补充剂通过改善肠道微生物群,血糖控制和减少氧化应激来保护糖尿病引起的损伤.
科学领域:
- 微生物学和免疫学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 肠道微生物群显著影响健康,特别是在减轻与糖尿病有关的损伤方面.
- 改变肠道微生物群是一种有前途的治疗策略,可以保护糖尿病患者的功能.
- 糖尿病引起的损伤是一种主要的并发症,需要有效的管理策略.
研究的目的:
- 评估Lactobacillus acidophilusATCC 4356补充剂在糖尿病诱导损伤的小鼠模型中对脏健康的保护作用.
- 评估益生菌补充剂对糖尿病大鼠肠道微生物群组成和多样性的影响.
- 调查脏保护作用背后的机制,包括血糖控制和氧化应激减轻.
主要方法:
- 在使用斯特佐托 (STZ) 的老鼠中诱导糖尿病.
- 在实验期之前和整个实验期内给予了Lactobacillus acidophilus ATCC 4356.
- 评估包括血糖,胰岛素,功能测试,口服葡萄糖耐受性测试,胰岛素敏感性测试,用于微生物组分析的16SrRNA基因测序和组织学检查.
主要成果:
- 益生菌补充剂显著增强了肠道微生物的多样性,并恢复了Firmicutes/Bacteroidetes的比率.
- 乳酸菌酸性菌种ATCC 4356改善了血糖控制,增强了胰岛素敏感性,并降低了禁食血糖水平.
- 益生菌治疗减少了氧化应激,改善了脏结构,减少了炎症和纤维化,减少了DNA损伤.
结论:
- 补充Lactobacillus acidophilus ATCC 4356证明了对糖尿病诱导的损伤具有显著的保护作用.
- 保护作用归因于恢复肠道微生物群多样性,改善血糖控制和减少氧化应激.
- 准肠道微生物群为治疗糖尿病及其相关并发症提供了潜在的治疗方法.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
162
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
162
Oral Hypoglycemic Agents: Biguanides and Glitazones
152
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
152
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Feedback Loops
55.5K
In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
55.5K
Pathophysiology of Diabetes
842
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
842


